What is KaloCyte?
KaloCyte is a preclinical-stage healthcare biotechnology company founded by a team of experts in physiology, bioengineering, and trauma care. The company is developing ErythroMer, a bio-inspired synthetic red blood cell designed to be freeze-dried for extended shelf life and ease of transport. ErythroMer is intended for use in situations where traditional stored red blood cells are unavailable, not ideal, or in short supply, with human trials anticipated within the next two to three years.
How much funding has KaloCyte raised?
KaloCyte has raised a total of $300K across 1 funding round:
Angel/Seed
$300K
Angel/Seed (2020): $300K, investors not publicly disclosed
What's next for KaloCyte?
With its large-scale, late-stage funding context, KaloCyte is poised to advance ErythroMer through critical preclinical stages and into human trials. This strategic investment will likely accelerate research and development, scale manufacturing capabilities, and support the rigorous regulatory processes required for bringing a novel therapeutic to market. The company's focus on addressing critical needs in blood transfusion underscores its potential impact on emergency medicine and trauma care.
See full KaloCyte company page
